Alpha Cognition shares preclinical data for TBI drug ALPHA-1062

Alpha Cognition (ACOG) announced preclinical data supporting the continued development of ALPHA-1062 for the treatment of mild traumatic brain injury, or mTBI. The study, supported by the U.S. Department of Defense and conducted with VA investigators, demonstrated that ALPHA-1062 administration following blast-induced mTBI resulted in a notable reduction in indices of TBI-associated neuropathology, including toxic forms of brain protein Tau. These changes suggest a potential role for ALPHA-1062 in treating TBI and possibly reducing the risk of later Alzheimer’s disease. Next steps include formulation for sublingual administration and a bridging pharmacokinetic study.